Nuclear Medicine Communications

Papers
(The H4-Index of Nuclear Medicine Communications is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
PET/computed tomography radiomics combined with clinical features in predicting sarcopenia and prognosis of diffuse large B-cell lymphoma42
Simulated daily readout for maintaining nuclear medicine education in residency training amidst declining case volume: evidence from the COVID-19 pandemic28
[18F]-PSMA-1007 PET imaging optimization and inter-rater reliability – a comparison of three different reconstructions read by four radiologists22
Is a strict restricted-iodine diet necessary for preparation of radioactive iodine therapy?20
Comparison of the role of 18F-fluorodeoxyglucose PET/computed tomography and 68Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma19
Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation18
Diagnostic value of single-photon emission computed tomography-CT foot and ankle studies18
Associations between brown adipose tissue activity, serum lipid profiles, and cardiovascular events: insights from 18F-fluorodeoxyglucose PET/computed tomography analysis15
Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies14
Outcomes of I-131 therapy in pediatric and adolescent differentiated thyroid cancer: a long-term follow-up of a single-center Indian cohort14
Relation of whole-body metabolic tumor volume and total lesion glycolysis on fluorodeoxyglucose PET/computed tomography with clinical and laboratory parameters in newly diagnosed multiple myeloma13
Semiquantitative analysis of 18F-aluminum fluoride fibroblast activation protein inhibitor 42 PET/computed tomography in primary liver cancer and factors influencing imaging positivity rates13
Validation of the Prostate Imaging for Recurrence Reporting (PI-RR) System using 68Ga prostate-specific membrane antigen-11 (HBED-CC) PET/MRI in biochemical recurrence of prostate cancer: a pilot stud12
0.19540810585022